Why HUVECs are the right cell to test
Any wound that heals well shares one requirement underneath everything else: new blood vessels have to grow into the damaged tissue, carrying oxygen and the raw materials repair actually needs. Without that, skin can close over on the surface and still be fragile, poorly nourished tissue underneath.
Human umbilical vein endothelial cells, HUVECs, are the standard laboratory model for studying exactly that process, because they are the same type of cell, endothelial cells, that physically line the inside of every blood vessel in the body. If a compound cannot get these cells to grow and divide in a dish, it is not going to build new vasculature in a wound.
The number that anchors this part of the paper
Treated with GHK-Cu-liposomes at increasing concentrations, 10, 50 and 100 micromolar, HUVEC proliferation rose in a clear dose-dependent pattern, and the effect was measurably stronger with the liposomal form than with free GHK-Cu at every concentration tested. At the top dose, 100 micromolar, the liposomal form produced a 33.1 percent increase in proliferation rate.
A third more cell growth, from one topical compound, against the same cells left untreated. That is the number underneath every claim in this paper about accelerated healing, and it is worth understanding what produced it before accepting it.
Two growth factors, more than doubled
Cell proliferation does not happen in isolation. It is driven by specific signalling proteins, and the paper measured two of the most important ones directly: vascular endothelial growth factor, VEGF, and fibroblast growth factor 2, FGF-2.
VEGF is the signal that specifically tells vascular endothelial cells to proliferate, migrate and form new vessels, and it also increases vascular permeability, which lets the molecular building blocks needed for that construction leak out of existing vessels into the surrounding tissue. FGF-2 works alongside it, promoting proliferation, differentiation and migration in cells originating from a broader tissue lineage, and the two are known to act synergistically rather than redundantly.
Compared with the PBS and empty-liposome control groups, GHK-Cu-liposome treatment more than doubled the expression of both VEGF and FGF-2, and the effect was consistently larger than what free GHK-Cu produced. That is two independent, established angiogenesis signals moving in the same direction, at the same time, which is a stronger claim than either one on its own.
What the cell cycle data actually shows
The proliferation number tells you cells grew faster. The cell cycle data tells you why, at the level of the machinery inside each cell.
CDK4 and Cyclin D1 are proteins that specifically drive the transition from the resting phase of the cell cycle into active DNA replication, the G1 to S stage handoff. Western blotting showed both rose after GHK-Cu-liposome treatment. Flow cytometry, which sorts a population of cells by exactly which phase of division each one is currently in, backed that up directly: the fraction of cells sitting in G1, the growth phase leading up to division, climbed to 57.49 percent, its highest point, while the fraction in G2, a later phase, fell to 4.78 percent.
Read plainly, that pattern describes a population of cells being actively pushed to prepare for and enter division, rather than idling. Combined with Ki67, a marker that specifically labels cells in active proliferation and showed strong signal concentrated in the cell nucleus after treatment, three independent measurements, a growth factor readout, a cell cycle protein readout, and a direct proliferation marker, all point at the same conclusion from three different angles.
Did it hold up in an actual wound
A dish of cells behaving well is a necessary condition, not a sufficient one. The real test is whether any of this translates into a living animal with an actual injury.
Two days after treatment, skin from the mouse burn wounds, covered in Part 4, was sectioned and examined. More blood vessels were visible under the microscope in tissue treated with GHK-Cu-liposomes than in tissue treated with free GHK-Cu or with empty liposomes. Immunofluorescence staining for CD31, a protein specifically expressed on the surface of vascular endothelial cells and used as a standard marker for counting blood vessels in tissue, confirmed it: stronger CD31 signal in the liposome-treated wounds. Ki67 showed the same pattern in the living tissue that it had shown in the cell dish.
The cell culture result and the animal result agree with each other. That is the meaningful validation step here, the same structural move the retatrutide mouse experiments made in the earlier series in this publication: a mechanism observed cleanly in a controlled system, then checked against whether it actually shows up in living tissue. It did.
What this doesn't answer yet
Angiogenesis is a necessary ingredient in wound healing. It is not the whole of it. Inflammation control, collagen deposition, wound contraction, scar quality and infection resistance all matter too, and none of them are measured directly by a blood vessel count or a growth factor blot.
The actual outcome that matters to anyone with a wound is simpler than any of this: how long did it take to heal, and what did the healed skin look like. That is Part 4, and it is also where this paper's evidence gets thinnest.
This series covers a peer-reviewed preclinical study conducted in cell culture and in mice. It has not been tested in humans for wound healing, and nothing here is medical advice or a product claim.
